Baseline Clinical Characteristics and Side Effects Comparing Patients Receiving ECTa and Those Receiving Fluoxetine
| . | ECT . | Fluoxetine . | P . | ||
|---|---|---|---|---|---|
| Variables | n | n | |||
| Sex, female, n (%) | 116 | 82 (70.7) | 126 | 96 (76.2) | .332a |
| Age, mean (SD), year | 116 | 46.9 (12.3) | 126 | 45.3 (11.0) | .286b |
| Age at onset, mean (SD), year | 116 | 38.1 (12.8) | 126 | 38.9 (11. 8) | .636b |
| Baseline HAMD-17 score, mean (SD) | 116 | 30.9 (7.0) | 126 | 31.3 (6.5) | .602b |
| Baseline MWSAS score, mean (SD) | 116 | 23.5 (7.3) | 126 | 23. 8 (7.9) | .747b |
| Baseline SF-36 PCS, mean (SD), | 105 | 42.4 (9.1) | 119 | 40.1 (10.6) | .088b |
| Baseline SF-36 MCS, mean (SD), | 105 | 20.5 (7.7) | 119 | 21.5 (9.0) | .396b |
| Employment in the 6 months before the trial, n (%) | 116 | 19 (16.4) | 126 | 46 (36.5) | <.001a |
| Anxiolytic/sedative-hypnotic medication used, n (%) | 116 | 105 (90.5) | 126 | 113 (89.7) | .828a |
| Side effects following treatment | 116 | 48 (41.4) | 126 | 21 (16.7) | <.001a |
| Subjective memory impairment, n (%) | 116 | 24 (20.7) | 126 | 20 (15.9) | 0.332a |
| Nausea/vomiting n (%) | 116 | 70 (60.3) | 126 | 21 (16.7) | <.001a |
| Headache n (%) | |||||
| . | ECT . | Fluoxetine . | P . | ||
|---|---|---|---|---|---|
| Variables | n | n | |||
| Sex, female, n (%) | 116 | 82 (70.7) | 126 | 96 (76.2) | .332a |
| Age, mean (SD), year | 116 | 46.9 (12.3) | 126 | 45.3 (11.0) | .286b |
| Age at onset, mean (SD), year | 116 | 38.1 (12.8) | 126 | 38.9 (11. 8) | .636b |
| Baseline HAMD-17 score, mean (SD) | 116 | 30.9 (7.0) | 126 | 31.3 (6.5) | .602b |
| Baseline MWSAS score, mean (SD) | 116 | 23.5 (7.3) | 126 | 23. 8 (7.9) | .747b |
| Baseline SF-36 PCS, mean (SD), | 105 | 42.4 (9.1) | 119 | 40.1 (10.6) | .088b |
| Baseline SF-36 MCS, mean (SD), | 105 | 20.5 (7.7) | 119 | 21.5 (9.0) | .396b |
| Employment in the 6 months before the trial, n (%) | 116 | 19 (16.4) | 126 | 46 (36.5) | <.001a |
| Anxiolytic/sedative-hypnotic medication used, n (%) | 116 | 105 (90.5) | 126 | 113 (89.7) | .828a |
| Side effects following treatment | 116 | 48 (41.4) | 126 | 21 (16.7) | <.001a |
| Subjective memory impairment, n (%) | 116 | 24 (20.7) | 126 | 20 (15.9) | 0.332a |
| Nausea/vomiting n (%) | 116 | 70 (60.3) | 126 | 21 (16.7) | <.001a |
| Headache n (%) | |||||
Abbreviations: ECT, electroconvulsive therapy; HAMD-17, 17-item Hamilton Rating Scale for Depression; MCS, mental component summary, lower scores of PCS reflect worse quality of life; MWSAS, Modified Work and Social Adjustment Scale = Work and Social Adjustment Scale (WSAS) without Item 1; PCS, physical component summary, lower scores of PCS reflect worse quality of life;
SF-36, Medical Outcomes Study Short-Form 36.
Bold, statistically significant.
aPearson’s χ2 test
bIndependent t test.
Baseline Clinical Characteristics and Side Effects Comparing Patients Receiving ECTa and Those Receiving Fluoxetine
| . | ECT . | Fluoxetine . | P . | ||
|---|---|---|---|---|---|
| Variables | n | n | |||
| Sex, female, n (%) | 116 | 82 (70.7) | 126 | 96 (76.2) | .332a |
| Age, mean (SD), year | 116 | 46.9 (12.3) | 126 | 45.3 (11.0) | .286b |
| Age at onset, mean (SD), year | 116 | 38.1 (12.8) | 126 | 38.9 (11. 8) | .636b |
| Baseline HAMD-17 score, mean (SD) | 116 | 30.9 (7.0) | 126 | 31.3 (6.5) | .602b |
| Baseline MWSAS score, mean (SD) | 116 | 23.5 (7.3) | 126 | 23. 8 (7.9) | .747b |
| Baseline SF-36 PCS, mean (SD), | 105 | 42.4 (9.1) | 119 | 40.1 (10.6) | .088b |
| Baseline SF-36 MCS, mean (SD), | 105 | 20.5 (7.7) | 119 | 21.5 (9.0) | .396b |
| Employment in the 6 months before the trial, n (%) | 116 | 19 (16.4) | 126 | 46 (36.5) | <.001a |
| Anxiolytic/sedative-hypnotic medication used, n (%) | 116 | 105 (90.5) | 126 | 113 (89.7) | .828a |
| Side effects following treatment | 116 | 48 (41.4) | 126 | 21 (16.7) | <.001a |
| Subjective memory impairment, n (%) | 116 | 24 (20.7) | 126 | 20 (15.9) | 0.332a |
| Nausea/vomiting n (%) | 116 | 70 (60.3) | 126 | 21 (16.7) | <.001a |
| Headache n (%) | |||||
| . | ECT . | Fluoxetine . | P . | ||
|---|---|---|---|---|---|
| Variables | n | n | |||
| Sex, female, n (%) | 116 | 82 (70.7) | 126 | 96 (76.2) | .332a |
| Age, mean (SD), year | 116 | 46.9 (12.3) | 126 | 45.3 (11.0) | .286b |
| Age at onset, mean (SD), year | 116 | 38.1 (12.8) | 126 | 38.9 (11. 8) | .636b |
| Baseline HAMD-17 score, mean (SD) | 116 | 30.9 (7.0) | 126 | 31.3 (6.5) | .602b |
| Baseline MWSAS score, mean (SD) | 116 | 23.5 (7.3) | 126 | 23. 8 (7.9) | .747b |
| Baseline SF-36 PCS, mean (SD), | 105 | 42.4 (9.1) | 119 | 40.1 (10.6) | .088b |
| Baseline SF-36 MCS, mean (SD), | 105 | 20.5 (7.7) | 119 | 21.5 (9.0) | .396b |
| Employment in the 6 months before the trial, n (%) | 116 | 19 (16.4) | 126 | 46 (36.5) | <.001a |
| Anxiolytic/sedative-hypnotic medication used, n (%) | 116 | 105 (90.5) | 126 | 113 (89.7) | .828a |
| Side effects following treatment | 116 | 48 (41.4) | 126 | 21 (16.7) | <.001a |
| Subjective memory impairment, n (%) | 116 | 24 (20.7) | 126 | 20 (15.9) | 0.332a |
| Nausea/vomiting n (%) | 116 | 70 (60.3) | 126 | 21 (16.7) | <.001a |
| Headache n (%) | |||||
Abbreviations: ECT, electroconvulsive therapy; HAMD-17, 17-item Hamilton Rating Scale for Depression; MCS, mental component summary, lower scores of PCS reflect worse quality of life; MWSAS, Modified Work and Social Adjustment Scale = Work and Social Adjustment Scale (WSAS) without Item 1; PCS, physical component summary, lower scores of PCS reflect worse quality of life;
SF-36, Medical Outcomes Study Short-Form 36.
Bold, statistically significant.
aPearson’s χ2 test
bIndependent t test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
